Eli Lilly Files Fraud Suit Over Alleged $200 Million Trulicity Rebate Scheme

Eli Lilly (NYSE: LLY) filed a federal civil lawsuit Tuesday alleging that a pharmacy-linked rebate scheme involving its diabetes drug Trulicity caused the company more than $200 million in losses.

The complaint, filed in U.S. District Court in Miami, centers on rebate claims submitted through a program connected to Community Health Initiative, an organization affiliated with the Church of God in Christ. The church itself is not named as a defendant.

Lilly said it identified the alleged fraud in 2025 after reviewing rebate-claim data tied to Trulicity. According to the filing, the claims showed repeated patterns the company viewed as unusual, including prescriptions with identical quantities and 30-day supply periods, almost no refills or reversals, and submissions involving only Trulicity rather than a broader mix of prescription drugs.

The company alleges DrugPlace, a Florida mail-order pharmacy, purchased large quantities of Trulicity through authorized distributors and used the Community Health program to support rebate claims. Lilly said DrugPlace represented that the medicine was being dispensed to eligible church members, while the same product was allegedly being resold outside the program. DrugPlace served as the pharmacy benefit manager for Community Health, according to the lawsuit, handling prescription drug claims and rebate negotiations with manufacturers. The filing says DrugPlace and Community Health operated from the same address in Tennessee.

Lilly alleges the program relied on church members to support rebate submissions, but said many patients connected to the claims either could not be verified or did not exist. The company said the alleged conduct continued for at least six years.

The complaint says DrugPlace justified the volume of Trulicity purchases by claiming the Church of God in Christ had 7 million members, including 2.5 million people who qualified for the Community Health program. Lilly cited a 2025 Pew Religion in America survey estimating the church’s membership at about 1.9 million people.

Lilly sued DrugPlace and Community Health, alleging they benefited from both rebate payments and revenue from reselling Trulicity. The complaint says rebate claims were submitted for hundreds of thousands of boxes of the drug, though it does not state how much DrugPlace allegedly made from resale activity.

Several individuals connected to the church or the program are also named as defendants. They include Readus C. Smith III of Jacksonville, Florida, who the suit identifies as secretary-general of health and business for the church and chief executive of Community Health; Jerry Maynard Sr. of Ashland City, Tennessee, a church bishop and businessman; Jerry Maynard II of Nashville, Tennessee, a pastor, business consultant and former member of the Metro Nashville Davidson Council; and Misha Maynard of Watertown, Tennessee, a pastor.

According to the filing, Maynard Sr. promoted Community Health to church members. Maynard II is identified as Community Health’s board chairman and as having performed legal work for DrugPlace. Misha Maynard is identified as Community Health’s vice president of operations. The lawsuit also names Paul Joshua Leight, DrugPlace’s co-owner and president, and Kevin Michael Singer, the pharmacy’s co-owner and vice president.

Lilly is seeking a temporary restraining order and a preliminary injunction. The company said other pharmaceutical manufacturers were also defrauded through the alleged rebate arrangement, but did not name them.

A Lilly spokesperson reported the company brought the case “to stop fraud and protect patients’ access to its medicines.” The spokesperson also said DrugPlace closed its Nashville pharmacy and began liquidating assets after the defendants learned they had been discovered.

About Eli Lilly

Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company develops and sells medicines across areas including diabetes, obesity, oncology, immunology and neuroscience.

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.